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It has been known since 1893 that blood contains a  proteolytic enzyme (1) 
and an inhibitor of this enzyme (2).  Failure to detect any proteolytic activity 
in fresh serum was explained by the assumption  that  the enzyme was kept 
neutralized by an excess of the inhibitor.  Such a protease-antiprotease system 
has attracted a great deal of attention because of the possibility that it is asso- 
ciated with certain immunological processes.  Recent investigations have in- 
dicated that a proteolytic enzyme is present in serum as an inactive precursor 
which can be activated under certain circumstances.  Such activation occurs 
when serum is treated with chloroform (3)  or with a  substance produced by 
certain strains of hemolytic streptococci (4).  However, this does not explain 
the  mechanism  of  fibrinolysis observed under  various  experimental  (5)  and 
clinical (6-8) conditions. 
The present paper deals with a  new set of conditions in which proteolyfic 
enzymes can be  activated in  guinea pig serum.  The observations reported 
below would seem to reopen the question of the part played by proteolysis in 
the mechanism of anaphylactic reactions and possibly other pathological con- 
ditions.  These observations may bring into agreement early theories of ana- 
phylaxis with recent findings by indicating an explanation for the mechanism 
of "anaphylatoxin"  and "serotoxin" formation and by establishing this mech- 
anism as an important link in the chain of reactions leading to the release of 
histamine and other toxic substances. 
Methods 
Several, often confusing  nomenclatures  are currently used in the study of blood proteases. 
The terminology  proposed by Loomis, George,  and Ryder (9) will be employed throughout 
this paper. 
(a) Preparation  of the Enzyme.--In previous  experiments  (10) direct estimation of fibrinoly. 
sin in sera treated with the specific antigen or peptone gave negative results.  Under these 
conditions, there was good reason to believe  that the enzyme,  if released,  would be neutralized 
by antifibrinolysin.  However,  it seemed that fibrinolys'm  could probably be detected if its 
combination with antitibrinolysin were prevented.  After various unsuccessful attempts  to 
* This  work  was  supported  by  a  research grant from the United States Public Health 
Service at the Rheumatic Fever Research Institute, Northwestern University,  Chicago. 
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eliminate the inhibitor by adsorption, it was found that separation of the enzyme from itsin- 
hibitor was obtained in the following manner.  The activating agent, dissolved in physiological 
saline, was added to a  measured amount of serum.  After a  measured duration of contact, 
the mixture was diluted with distilled water to twenty times the initial volume, adjusted to 
pH 5.2 with 0.5 per cent acetic acid by means of a  glass electrode, and centrifuged.  The 
supernatant, containing antiiibrinolysin, was discarded and the precipitate was redissolved in 
saline buffered to pH 7.4 (phosphate buffer diluted to 0.1 M with 0.9 per cent NaC1).  In the 
control sample, saline was added to serum and the mixture submitted to identical treatment. 
Guinea pig serum was used throughout the experiments.  Individual blood samples were 
taken by heart puncture; pooled blood was collected by bleeding guinea pigs from the carotid 
and jugular vessels.  The serum collected from clotted blood was stored between experiments 
at -- 20  °C. 
(b) Estimo~ion of Fibrinoly~ Acti~ly.--A technique based on the digestion of fibrinogen 
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FIG.  1.  Titration curve of fibrinolysin by the fibrinogenolytic method.  Abscissa, units of 
fibrinolysin; ordinate,  incubation time with fibrinogen (log scale).  Temperature,  37.5°C., 
pH 7.4. 
was used in most experiments.  Suggested first by Ferguson (11), the fibrinogenolytic method 
proved more sensitive than any other existing quantitative technique.  It allowed the detec- 
tion of amounts of enzyme equivalent to 10  ~  mg. crystalline trypsin and was about 36 times 
more sensitive than the clot-lysis method as used by Loomis (9). 
As described previously (10), the fibrinogenolytic method was standardized with crystalline 
trypsin.  In the present work, the results are expressed in units obtained by comparison with 
the activity of a fibrinolysin preparation,  t  Fibrinogen submitted to the action of fibrinolysin 
loses its ability to clot on addition of thrombin.  Duration of contact necessary to prevent 
clotting is  inversely proportional to  enzyme concentration when plotted  on a  logarithmic 
scale (Fig.  1). 
Amounts of 0.2 ml. of a 0.2 per cent solution of fibrinogen  ~ (in buffered saline at pH 7.4) are 
pipetted into a  series of small tubes.  Varying amounts of the enzyme solution to be tested 
are added to the fibrinogen and the total volume is made up to 0.4 ml. with saline.  After 
incubation at 37.5°C. for 30 minutes one drop of a  thrombin solution  8 is added to each tube. 
x Kindly supplied by Mr. E. C. Loomis of the Research Laboratories, Parke, Davis and Co. 
2 Fraction I, human plasma kindly supplied by Dr. J. T. Edsall. 
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The tube containing the  lowest concentration of  enzyme which fails  to clot in 30 minutes 
contains by definition one unit of enzyme.  In a previous publication  (10) the unit was de- 
fined by the same duration of contact and at the same concentration of the reagents but the 
total volume was 5 ml.  For purposes of comparison, aU readings obtained in the present ex- 
periments have been divided by 12.5. 
Some of the results of the fibrinogenolytic technique were confirmed by a  viscosimetric 
method.  This was considered more suitable  than turbidity measurements Used by Grob (12) 
and  Ratnoff  (13)  because high turbidity  of crude enzyme preparations  interferes with the 
accurate reading of results.  Two ml. of a 3 per cent solution of gelatin (in saline buffered to 
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FIG.  2.  Titration  curve of fibrinolysin by  the viscosimetric method.  Abscissa,  units o 
fibrinolysin; ordinate, decrease in viscosity of a  3 per cent solution of gelatin in 20 minutes' 
incubation with fibrinolysin (log scale).  Temperature, 37.5°C.,  pH 7.4. 
pH 7.4) is pipetted into an Ostwald vlscosimeter kept at 37.5°C.  The enzyme sointion, filtered 
and warmed to the same temperature, is made up to the volume of 1.5 ml. and added to the 
substrate.  Flow times are measured five or six times during the first 25 minutes and relative 
viscosities are plotted against time.  The decrease in viscosity is linear for the first 20 minutes 
and the initial viscosity can be read by extrapoiation.  Viscosity change is calcuiated (in per- 
RVo  -  RV:o 
centage of the total amount) by means of the formula X  =  100  ~-~  _  ]- ,  where RVo= 
initial relative viscosity and  RV,o  =  relative viscosity after 20 minutes' digestion.  Fig. 2 
shows that log X is linearly related to the logarithm of enzyme concentration for values of X 
between 2.5  and  25.  The calibration curve was obtained with purified fibrinolysin.  The 
results obtained by viscosimetry are also expressed in terms of the units defined above. 42  RELEASE  OF  SERUM  I~IBRINOLYSIN 
RESULTS 
The hypothesis tested in the first series of experiments was that failure to 
detect fibrinolytic activity on addition of the specific antigen or peptone (10) 
to serum was due to  the neutralization of the activated enzyme by antifibri- 
nolysin.  If this hypothesis proved true, neutralization should be prevented by 
precipitating the enzyme shortly after addition of the activating agent.  Under 
these conditions enzyme activity could be detected in the euglobulin precip- 
itate.  The findings confirmed this hypothesis. 
1.  Anal~hylaxis.--Eight guinea pigs received one subcutaneous injection each 
of 10 mg. egg albumin?  Twenty-five days after sensitization 1.5 ml. of blood 
TABLE I 
Fibrinolysin in Sera of Guinea  Pigs Se~itiz~ to Egg Albumin 
Serum from 
Sensitized guinea pigs 
Normal guines pigs 
Units/ml. serum 
Control 
<0.08 
0.4 
<0.4 
<0.08 
<0.4 
<0.8 
<0.08 
<0.08 
<0.08 
<0.2 
0.08 
0.2 
With antigen* 
3.2 
1.6 
0.8 
1.2 
3.2 
2.4 
1.6 
1.2 
<0.08 
0.2 
0.08 
0.4 
Dam obtained by fibrinogenolytic  method. 
* O. 1 rag. egg albumin per ml. serum. 
was collected from each guinea pig by heart puncture.  To each serum spec- 
imen 0.1  mg. per ml. egg albumin was  added and after 3  minutes'  contact, 
euglobulin was  precipitated as  described above.  The precipitate was  redis- 
solved  and  fibrinolysin  activity  estimated  by  the  fibrinogenolytic method. 
The results, summarized in Table I, show that the mean proteolytic activity 
of sera from sensitized guinea pigs treated with antigen was  1.9 units per ml. 
(-4-0.3); whereas the same sera, untreated, gave the average value of less than 
0.3  unit.  When  serum  from normal,  non-sensitized guinea  pigs  was  mixed 
with egg albumin,  there was  no significant difference between  albumin  and 
saline-treated samples  (0.19 and 0.14 respectively).  These findings indicate 
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that the antigen-antibody reaction is accompanied by the conversion of inactive 
profibrinolysin into an active proteolytic enzyme. 
2.  Peptone.--The  same results were observed when peptone  5 was added in 
dtro to normal guinea pig serum.  As seen in Table II, the optimum amount 
of peptone is 20 mg. per ml. of serum.  It is also seen that activity varies ac- 
cording to the interval between addition of peptone to serum and precipitation 
of euglobulin.  Activity increases between 25 seconds and 1 minute and then 
decreases between 2 and  15 minutes.  This suggests that  the profibrinolysin 
activation is comparatively rapid and also that simultaneously with the acti- 
TABLE II 
Fibrinolysin in Pooled Guinea Pig Sera Mixed with Peptone 
Peptone mg./ml, serum  Time of contact  Units/ml. serum 
Control 
10 
20 
50 
100 
Control 
20 
5 min. 
.5  " 
.5  " 
S  " 
25 sec. 
0.4 
1.6 
5.6 
2.4 
1.6 
0.4 
2.4 
20 
20 
20 
20 
20 
20 
Control (V) 
20  (v) 
20  (v) 
35  " 
lm~n. 
2  " 
10  " 
15  " 
2mla. 
2  " 
3.2 
8.0 
8.0 
5.6 
3.2 
1.6 
0.3 
6.0 
8.0 
Fibrinogenolytic method, except when marked (V). 
•  cation the enzyme combines with antiiibrinolysin.  After the first I  or 2 min- 
utes the rate of combination is faster than the activation which results in the 
gradual decrease of free enzyme. 
The results shown in Table II were obtained in pooled guinea pig serum. 
Experiments were also performed on samples from individual guinea pigs and 
Table III shows the variation in profibrinolysin activation observed in eight 
guinea  pigs.  When  peptone  was  applied  under  optimum  conditions  of  20 
rag. per ml. serum for 2 minutes, the average value of fibrinolysin released is 
4.95 units per ml. (4-0.94).  The variation, as estimated by the coefficient of 
variation, is 48.8 in anaphylaxis and 53.2 in the case of peptone. 
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3.  Agar.--It is known that the addition of agar induces changes in guinea 
pig serum.  When injected into guinea pigs the altered serum kills the animals 
(14).  To determine whether the  acquired toxicity was  associated  with  the 
activation  of  profibrinolysin,  the  following  experiment  was  done.  Pooled 
guinea pig serum was mixed with varying amounts of a  0.5 per cent solution 
of agar  6 kept at 37°C.  The mixture was shaken for 2 minutes and kept after- 
TABLE III 
Fibrinolysin Rdease by Peptone in Individual Guinea Pig Soa 
Normal~m~ pigs 
Control 
<0.4 
0.08 
0.2 
2.0 
<0.08 
0.4 
<0.04 
0.2 
Units/ml, serum 
With 20  mg. peptone/mL  serum 
for 2 rain. 
1.2 
3.2 
1.6 
8.0 
5.6 
8.0 
6.4 
5.6 
Fibrinogenolytic  method. 
TABLE IV 
Fibrinolysin in Guinea Pig Serum Mixed with Agar 
Units/ml.  serum 
Control 
O.  5 per cent agar o.  2 ml. 
0.5  " 
t  mi. (v) 
0.08 
1.6 
3.2 
4.0 
4.0 
4.5 
Fibrinogenolytic  method except when marked (V). 
wards in the refrigerator for 30 minutes (sol-gel method of Novy and De Kruif, 
25).  Dilution  and  precipitation  were  then  performed  as  usual.  Results 
shown in Table IV indicate that agar activates fibrinolysin and the maximum 
activation is reached with 5 rag. per ml. serum. 
4.  HyaZuronic  Acid.--Since agar proved to be an activating agent for pro- 
fibrinolysin, other polysaccharides were tested and were also found to be active. 
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Among these, hyaluronic acid  7 was the most potent and constant in its effect. 
Table V  shows the action of hyaluronic acid on four samples of pooled guinea 
pig serum.  The optimum time of contact was the same as for peptone, about 
2 minutes.  The  results  shown in  Table VI were  obtained  with  the  viscosi- 
metric method.  Table VI also shows the  influence  of the aging of serum on 
profibrinolysin activation.  The maximum was reached in about 3  days and 
FibrinoP 
Serum No, 
TABLE V 
,sin in Guinea Pig Serum Treated with Hyaluronic Acid 
Hyaluronic acid mg./ml. 
Control 
0.02 
0.04 
0.08 
0.2 
0.4 
0.8 
Interval 
5 min. 
5  " 
5  " 
5  " 
5  " 
5  " 
5  " 
2min. 
5  " 
Control 
0.18 
0.18 
0.18 
0.18 
0.18 
Control 
0.08 
0.4 
10  " 
15  " 
20  " 
2  rain. 
2  min. 
2  " 
2  " 
2  " 
Control 
0.08 
0.16 
0.24 
0.8 
Units/ml. serum 
p 
0.2 
0.4 
2.0 
4.0 
6.0 
8.0 
8.0 
<0.8 
2.4 
1.2 
0.8 
0.8 
<0,8 
0.4 
3.0 
6.0 
0.08 
0.8 
3.0 
3.0 
3.0 
Fibrinogenolytic method. 
the  activity  decreased  slowly after  the  1st week.  Between  experiments  the 
serum was kept at  --20°C. 
The following experiment was performed to investigate the effect of hydrol- 
ysis of hyaluronic acid on its activating power.  Three mg. of hyaluronic acid 
was incubated at pH 6 and 37.5°C. with the amount of hyaluronidasC known 
to produce 50 per cent hydrolysis in 30 minutes  (as estimated by the turbidi- 
metric method).  Samples containing 0.6 rag. hyaluronic acid (or the equiva- 
7 K hyaluronate  and testicular hyaluronidase kindly supplied by Schering Corporation. 46  ¸  RELEASE  0~'  SERUM  FIBRINOLYSIN 
lent amounts of hydrolysis products) were collected at definite intervals after 
the beginning of incubation and tested for profibrinolysin activation with the 
fibrinogenolytic method.  The results  shown in Table  VII indicate  a  steady 
decline in activity while hyaluronic acid is submitted to enzymatic hydrolysis. 
TABLE VI 
Fibrlnolysin Release by Hyaluronic Acid (Influence of the Age of Serum) 
Serum No.  Age  Units/ml. serum 
days 
1 
3 
6 
7 
8 
12 
15 
20 
1 
2 
4 
7 
21 
13 
21 
13.5 
10 
12 
10 
9 
6 
12 
18 
18 
15 
4 
Viscosimetric data.  Hyalurunic  acid  ffi 0.36 mg./mL serum;  interval  ffi  2 minutes. 
TABLE VII 
Influence of Enzymic Hydrolysis of Hyaluroni¢ Acid on Proffodnolysin Act~ealion 
Incubation time with hyaluronidue  Units/ml. serum 
Control 
0min. 
15  " 
30  " 
45  " 
60  " 
<0.4 
8.0 
6.0 
4.0 
2.0 
1.0 
Hyaluronic  acid was incubated  with hyaluronidase at pH 6 and 37.5°C.  Samples were 
collected at stated intervals and added to serum (0.6 rag. per ml.). 
This indicates  that hyaluronic acid itself and none of its hydrolysis products 
is responsible for the activation of profibrinolysin. 
5.  Other Polysc~ccharides.--Among  other high molecular carbohydrates tested, 
glycogen, chondroitinsulfuric acid, S type-specific pneumococcal polysaccharides 
s Cartilage powder, containing no heat-precipitable  proteins, kindly  supplied by  Wilson 
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(types I  and II),  9 and  heparin  1° were active.  The results are summarized in 
Table VIII. 
6.  Inhibition of the Activation by Heparin.--Table VIII shows that heparin 
activates profibrinolysin only up to 0.4 rag. per ml. serum and that this ceases 
when the concentration of heparin is increased.  The possible inhibitory effect 
TABLE VIII 
Action of Other Polysaccharides on Proflbrinolysin 
Activating  agent  UnRs/ml.  serum 
Glycogen 
Chondroitinsulfuric acid 
Type I pneumococcus 
mg. 
50 
8O 
20O 
4O0 
0.4 
0.8 
1.6 
2.4 
3.2 
0.032 
0.32 
0.64 
0.8 
1.2 
1.4 
2.4 
2.4 
2.0 
3.0 
8.0 
8.0 
8.0 
0.4 
1.2 
1.8 
2.0 
Type II pneumococcus 
Heparin 
~c 
0.04 
0.4 
0.8 
0.004 
0.02 
0.04 
0.08 
0.2 
0.4 
0.8 
<0.4 
0,8 
2,0 
3.0 
6.0 
6.0 
<0.4 
<0.4 
<0.4 
<0.4 
Fibrinogenolytlc method. 
of  large  amounts  of  heparin  on  profibrinolysin  activation  was  therefore  in- 
vestigated.  Table IX shows that  2 mg. of heparin per ml.  can prevent the 
activation  of  the  profibrinolysin  by hyaluronic  acid.  That  heparin  inhibits 
the conversion of the precursor into the active enzyme, i~ shown by the fact 
0  Kindly supplied by Dr. Michael Heidelberger. 
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that it has no effect on proteolytic activity when added to the euglobulin frac- 
tion after precipitation.  This is contrary to the findings of Glazko and Fer- 
guson  (15)  who found heparin to be a  protease inhibitor.  Heparin  inhibits 
TABLE  IX 
Inhibition of Profibrinolysin Activation by Heparin and Toluidine Blue 
Activator 
Hyahronic acid 0.2 rag. 
"  "  0.2  " 
Hyaluronic acid 0.4 mg. 
Peptone 20 rag. (V) 
Streptokinase 0.08 rag. 
"  0.2  " 
"  0.4  " 
Inhibitor 
Heparin O. 2 rag. 
"  0.04" 
Tohidine blue 0.4 rag. 
Heparin 0.18 rag. 
"  0.2  " 
"  0.2  " 
"  0.2  " 
Unlts/ml. serum,  when 
~0. 
inhibitor  Inhibitor ] Inhibitor 
added to  added  to 
., erum  eugk  t ulin 
4.0  <0.4  I  4.0 
3.0  <0.4  3.0 
3.0  0.8  I  3.0 
3.0  <0.4  3.0 
8.0  9.0  -- 
6.0  8.0  -- 
10.0  10.0  -- 
16.0  16.0  -- 
Fibrinogenolytic method except when marked (V). 
TABLE  X 
Comparison  between  the  Effect  of Activating  Agents  When  Added  to  Wkole  Serum  or  to  tke 
Euglobulin  Fr.cli~n 
Agent  Units/ml. serum when  Units/ml. serum when 
added to serum  added to euglobulin 
0  .................. 
Streptokinase 1 mg  ..................... 
Hyahronic acid 0.1 mg  ................. 
"  "  0.2  "  ............... 
Peptone 20 mg  ......................... 
0.8 
10 
2 
4 
6 
0.8 
36 
0.8 
0.8 
0.8 
Time of contact 2 minutes.  Estimation by fibrlnogenolytic method. 
only the activation by hyaluronic acid and has no effect on fibrinolysin release 
by streptokinase  n  or peptone. 
Toluidine  blue,  an  antagonist  of  heparin,  also  prevents  the  activation  of 
profibrinolysin by hyaluronic acid. 
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7.  Negative Results.--No activating effect was found when the following sub- 
stances were tested: thromboplastin,  12 dicoumarol, starch,  1~ epinephrine hydro- 
chloride, histamine dihydrochloride,  acetylcholine chloride. 
8.  Conditions  o/Activation.--It  is well known that the inactive euglobulin 
precipitated from serum can be activated by chloroform or streptokinase (16, 
17, 13), and in fact streptokinase produces a better activation when added to 
the euglobulin fraction than when added to whole serum  (Table X).  On the 
other hand peptone and hyaluronic acid fail to induce activation under these 
conditions.  They act only when added to whole serum. 
Ratnoff has shown that streptokinase added to heated serum still releases 
active enzyme (13).  Peptone or hyaluronic acid fails to produce any activation 
under these conditions.  It therefore  appears  that the activation of profibrin- 
olysin by the agents described  in these experiments  requires  the presence of 
some  serum  constituent not precipitated  with  the  euglobulin  fraction and 
destroyed by heating at 56  °  . 
DISCUSSION 
A physiological kinase system of various tissue cells has been described by 
Fleisher and Loeb (18), Astrup and Pertain (19, 20), Goldhaber, Cornman, and 
Ormsbee  (21), and the presence of a  "cytofibrinokinase" in erythrocytes has 
been reported by Pertain (22).  The above experiments  give further support 
to the opinion that profibrinolysin can be activated under conditions that are 
usually assumed to occur in the intact animal. 
The activating agents employed in the present study require for their action 
the presence  of some serum constituent which  is  not precipitated with the 
euglobulin fraction and which is destroyed at 56°C.  That this constituent is 
not the proenzyme itself is shown by the fact that the euglobulin precipitate 
and heated serum can still be activated by chloroform or streptokinase.  How- 
ever, the possibility that the protease produced under the conditions described 
above is not identical with fibrinolysin resulting  from chloroform or strepto- 
kinase activation cannot be excluded.  Pending further investigation, a fibrino- 
kinase is assumed to be the necessary serum constituent. 
The mechanism by which the activating agents induce kinase to act on the 
proenzyme is unknown.  One hypothesis under investigation is that the kinase 
is held inactive by an antikinase and the activating agent acts by liberating it 
from this combination.  The carbohydrate nature of the most potent activators 
suggests that the hypothetical antikinase may be a carbohydrate itself and can 
be displaced from its combination with the kinase  by the activating agents. 
Heparin might well compete in this reaction with hyaluronic acid as it does in 
inhibiting hyaluronidase (23). 
Thrombophstin local Lederle. 
it Soluble starch Merck. 50  RELEASE OF  SERUM FIBRINOLYSIN 
The results described above permit a new interpretation of some early exper- 
iments in which serum was rendered toxic by addition of specific  antigen or 
various non-antigenic substances  (24,  25).  The  "anaphylatoxin"  or  "sero- 
toxin" developed under  these  conditions cannot be  histamine or any other 
simple  substance  because  these  substances  cannot  be  released  from serum. 
Futhermore, even if released from whole blood, their concentration would be 
too low to explain the high toxicity of a few milliliters of serum (26-28).  The 
same objection is valid for fibrinolysin itself.  It therefore appears  that the 
toxic factor may be a kinase which can induce activation of large amounts of 
large amounts of fibrinolysin in dvo.  This possibility is now under investiga- 
tion. 
The appearance of a protease during anaphylactic and anaphylactoid reaction 
in dtro suggests that this process may also occur in the intact animal and sup- 
plies additional evidence in favor of the enzymatic origin of the toxic products 
directly responsible for the mechanism of shock. 
SUMMARY 
Formation of fibrinolysin  from its  inactive  precursor in serum was observed 
under the following conditions: (a) by adding the specific  antigen to serum 
from sensitized  guinea pigs;  (b) by mixing normal guinea pig serum with pep- 
tone, agar, hyaluronic acid,  chondroitinsulfuric  acid,  glycogen, pneumococcal 
polysaccharides, and heparin. 
Activation of profibrinolysin by these agents differs  from chloroform  or 
strcptokinase  activation  in that it  requires  the presence of some serum constit- 
uent non-precipitable with the euglobulin fraction  and destroyed by heating 
at 56°C. 
The bearing of these observations on the mechanism  of anaphylactic and 
anaphylactoid reactions  is discussed.  The findings  reported support the con- 
cept that proteolysis  is  part of the process determining the release  of  histamine 
and other toxic  products. 
It is  suggested that the presence of fibrinokinase  may be responsible  for the 
toxicity  of serum induced in dtro by a number of agents. 
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